P86 Stock Overview

Engages in the research and development of therapeutic products for human use in Australia. More details

P86 fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Risk Analysis

Earnings are forecast to decline by an average of 13.2% per year for the next 3 years

Highly volatile share price over the past 3 months compared to the German market

Makes less than USD$1m in revenue (A$0)

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

My Notes

Capture your thoughts, links and company narrative

Paradigm Biopharmaceuticals Limited Competitors

Heidelberg Pharma

XTRA:HPHA

€115.6m

Medigene

XTRA:MDG1

€19.3m

4SC

DB:VSC

€59.1m

2invest

XTRA:2INV

€67.3m

Price History & Performance

Summary of share price highs, lows and changes for Paradigm Biopharmaceuticals
Historical stock prices
Current Share Price	AU$0.26
52 Week High	AU$0.34
52 Week Low	AU$0.10
Beta	0.84
1 Month Change	21.30%
3 Month Change	116.53%
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	82.58%

Recent updates

Shareholder Returns

	P86	DE Biotechs	DE Market
7D	4.0%	-1.9%	3.5%
1Y	n/a	-4.2%	13.1%

Return vs Industry: Insufficient data to determine how P86 performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how P86 performed against the German Market.

Price Volatility

Is P86's price volatile compared to industry and market?
P86 volatility
P86 Average Weekly Movement	19.5%
Biotechs Industry Average Movement	6.2%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	11.5%
10% least volatile stocks in DE Market	2.4%

Stable Share Price: P86's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: P86's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

Founded	Employees	CEO	Website
2014	n/a	Paul Rennie	www.paradigmbiopharma.com

Paradigm Biopharmaceuticals Limited engages in the research and development of therapeutic products for human use in Australia. It lead candidate is Zilosul, an injectable pentosan polysulfate sodium drugs for the treatment of osteoarthritis, mucopolysaccharidosis, ross river virus, chikungunya virus, chronic heart failure, allergic respiratory, and acute respiratory distress syndrome diseases. The company was incorporated in 2014 and is headquartered in Melbourne, Australia.

Paradigm Biopharmaceuticals Limited Fundamentals Summary

How do Paradigm Biopharmaceuticals's earnings and revenue compare to its market cap?
P86 fundamental statistics
Market cap	€95.70m
Earnings (TTM)	-€35.30m
Revenue (TTM)	n/a

0.0x

P/S Ratio

-2.7x

P/E Ratio

Is P86 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
P86 income statement (TTM)
Revenue	AU$0
Cost of Revenue	AU$8.99k
Gross Profit	-AU$8.99k
Other Expenses	AU$58.64m
Earnings	-AU$58.65m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.17
Gross Margin	0.00%
Net Profit Margin	0.00%
Debt/Equity Ratio	0%

How did P86 perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/01/21 03:26
End of Day Share Price	2025/01/21 00:00
Earnings	2024/06/30
Annual Earnings	2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Paradigm Biopharmaceuticals Limited is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
John Hester	Bell Potter
Soo Romanoff	Edison Investment Research
Arron Aatkar	Edison Investment Research

Paradigm Biopharmaceuticals DB:P86 Stock Report